Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Simon on the Importance of Next-Generation Sequencing in NSCLC

October 27th 2021

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

Dr. Raez on the Clinical Implications of the KEYNOTE-024 Trial in NSCLC

October 27th 2021

Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.

Dr. Nguyen on Managing Mobocertinib-Related GI Toxicities in EGFR Exon 20 Insertion+ NSCLC

October 27th 2021

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Piccirillo on the Safety Profile of Bevacizumab Plus Erlotinib in EGFR+ Nonsquamous NSCLC

October 27th 2021

Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.

It’s Not a Small World for Small Cell Lung Cancer Treatment

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss the latest findings in small cell lung cancer based on studies that were presented during the 2021 ESMO Congress, 2021 World Conference on Lung Cancer, and 2021 ASCO Annual Meeting.

Living In a Targeted Therapy Revolution of NSCLC

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, share insight on the data with novel targeted agents with impressive efficacy in patients with lung cancer, as seen at the 2021 ESMO Congress and the 2021 World Conference on Lung Cancer.

Neoadjuvant and Stage IV Immunotherapy Data Shaking Up Lung Cancer Paradigm

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, highlight results with immunotherapy in the neoadjuvant and stage IV setting in lung cancer that were presented at the 2021 World Conference on Lung Cancer and the 2021 ESMO Congress.

Adjuvant Immunotherapy Breakthroughs in Lung Cancer from ESMO 2021

October 27th 2021

Isabel Preeshagul, DO, MBS; Catherine Ann Shu, MD; and Ashish Saxena, MD, PhD, discuss breakthroughs in adjuvant immunotherapy in lung cancer from data presented at the 2021 ESMO Congress and 2021 World Conference on Lung Cancer.

Dr. Gogishvili on the Rationale for the EMPOWER-Lung 3 Trial in NSCLC

October 26th 2021

Miranda Gogishvili, MD, discusses the rationale for the phase 3 EMPOWER-Lung 3 trial in advanced or metastatic non–small cell lung cancer.

Toxicity Management Remains Key With Expanding Frontline Treatment Options in Lung Cancer

October 25th 2021

Antoinette Wozniak, MD, FACP, FASCO, highlights the importance of monitoring patients with lung cancer for toxicities and significant advances on the horizon that are expected to further expand the lung cancer armamentarium.

Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC

October 25th 2021

Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.

Canakinumab Combo Misses Survival End Points in Previously Untreated Locally Advanced or Metastatic NSCLC

October 25th 2021

Canakinumab plus pembrolizumab and platinum-based doublet chemotherapy did not significantly improve progression-free survival or overall survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer, missing the primary end points of the phase 3 CANOPY-1 trial.

Clinical Management of ROS1+ Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.

ROS1 Alterations in Advanced NSCLC

October 25th 2021

Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing

October 23rd 2021

The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care.

Dr. Burns on the Promise of Combination Regimens in EGFR Exon 20 Insertion+ and KRAS+ NSCLC

October 22nd 2021

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

Dr. Villaruz on Selecting Between Single-Agent and Combination Immunotherapy in NSCLC

October 22nd 2021

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

Second-Line Metastatic NSCLC: Treatment Landscape and Challenges

October 22nd 2021

Melissa Suk Heist, MD, MPH, discusses the treatment landscape and challenges when treating patients with second-line metastatic non-small cell lung cancer.

Will Slow and Steady Progress in Treating SCLC Win the Race?

October 22nd 2021

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Dr. Lee on the Current State of Molecular Testing in Early-Stage NSCLC

October 20th 2021

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.